Page 107 - Assessing right ventricular function and the pulmonary circulation in pulmonary hypertension Onno Anthonius Spruijt

References
[1] Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. Journal of the American College of Cardiology. 2003; 41:1028-35
[2] Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis and rheumatism. 2008; 58:284-91
[3] Montani D, Achouh L, Dorfmuller P, Le Pavec J, Sztrymf B, Tcherakian C, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine. 2008; 87:220-33
[4] Trip P, Girerd B, Bogaard HJ, de Man FS, Boonstra A, Garcia G, et al. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension. The European respiratory journal. 2014; 43:1195-8
[5] Trip P, Nossent EJ, de Man FS, van den Berk IA, Boonstra A, Groepenhoff H, et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. The European respiratory journal. 2013; 42:1575-85
[6] Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010; 29:181-7
[7] Hoeper MM, Simon RGJ. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014; 23:450-7
[8] Souza R, Fernandes CJ, Hoeper MM. Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension. The European respiratory journal. 2014; 43:963-5
[9] Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). The European respiratory journal. 2015; 46:903-75
[10] Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. Jacc. 2016; 4:441-9
[11] van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. Journal of the American College of Cardiology. 2011; 58:2511-9
[12] ATS statement: guidelines for the six-minute walk test. American journal of respiratory and critical care medicine. 2002; 166:111-7
[13] Erratum: ATS Statement: Guidelines for the Six-Minute Walk Test. American journal of respiratory and critical care medicine. 2016; 193:1185
[14] Resten A, Maitre S, Capron F, Simonneau G, Musset D. [Pulmonary hypertension: CT findings in pulmonary veno- occlusive disease]. Journal de radiologie. 2003; 84:1739-45
[15] Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Ajr. 2004; 183:65-70
[16] Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. International journal of cardiology. 2013; 168:871-80
Chapter 6
105
6